Eisai
Zonegran study could pave way for paediatric licence
September 2, 2011Research and Development, Sales and Marketing Eisai, Zonegran, epilepsy, research and development news
Eisai’s epilepsy drug Zonegran has been found more effective than placebo in children with the neurological condition who have seizures. …
FDA refuses to file Eisai’s epilepsy drug
August 1, 2011Sales and Marketing Eisai, FDA, epilepsy
The FDA has refused to file Eisai’s epilepsy drug perampanel, saying it needs more information for the treatment. The FDA …
NICE says no to breast cancer treatment Halaven
July 20, 2011Sales and Marketing Eisai, Halaven, NICE
Eisai’s Halaven has been rejected by NICE in draft guidance for locally advanced or metastatic breast cancer. Halaven (eribulin) is …
Eisai extends neuroscience partnership with UCL
May 25, 2011Research and Development Eisai, UCL, academic alliance, academic research, neurodegenerative diseases
Eisai and University College London are to extend their partnership in neuroscience research. The Japanese company’s Neuroscience Product Creation Unit …
Eisai launches cancer drug Halaven in UK
April 20, 2011Sales and Marketing Eisai, Halaven, breast cancer
Eisai’s sea sponge derived breast cancer drug Halaven has been launched in the UK following approval from European regulators a …
Eisai sets up in Brazil
April 8, 2011Sales and Marketing Brazil, Eisai
Japanese pharma company Eisai has set up its first operations in Latin America, establishing a sales subsidiary in Brazil. Based …
Eisai marine sponge derived cancer drug approved in Europe
March 23, 2011Sales and Marketing Cancer, Eisai, Halaven, Halichondria okadai, breast cancer, eribulin mesylate
Eisai’s injectible breast cancer drug Halaven has been approved by European regulators. The highly novel drug is made from a …
Japan’s pharma industry pledges to maintain medicines supply
March 17, 2011Sales and Marketing Astellas, Boehringer Ingelheim, Daiichi Sankyo, Eisai, Japan, earthquake
Pharmaceutical firms in Japan have escaped the very worst of the devastation caused by the earthquake and tsunami, and have …
Eisai confirms 20% cut in US workforce
March 8, 2011Manufacturing and Production, Research and Development, Sales and Marketing Aricept, Eisai, Halaven, US, donepezil, eribulin, pharma job cuts
Eisai’s planned job cuts will fall heaviest on its US operations, where 20% of the workforce will be let go …
Eisai prepares ground for Halaven’s European launch
March 7, 2011Sales and Marketing Cancer, EMBRACE, Eisai, Halaven, advanced breast cancer, breast cancer, eribulin
Eisai has published further details of a phase III trial of its first-in-class chemotherapy drug Halaven ahead of its hoped-for …
Eisai to cut 900 jobs ahead of Aricept patent loss
March 7, 2011Sales and Marketing Aricept, Eisai, donepezil, generics, job cuts
Eisai is to cut around 900 jobs in Europe, the US and Japan over the next five years as it …
Eisai sepsis drug fails in phase III
January 26, 2011Research and Development, Sales and Marketing Eisai, eritoran, perampanel, sepsis
A new treatment for severe sepsis could be abandoned entirely after phase III results fell short. Eisai’s eritoran did not …
FDA approves Eisai breast cancer drug Halaven
November 16, 2010Sales and Marketing Cancer, Eisai, FDA, Halaven, Xeloda, breast cancer, eribulin mesylate, metastatic breast cancer
The FDA has approved Eisai’s advanced breast cancer drug Halaven for use in heavily pre-treated breast cancer patients. Halaven (eribulin …
Arena’s obesity treatment lorcaserin rejected by FDA
October 25, 2010Sales and Marketing Arena Pharma, Eisai, FDA, FDA complete response letter, lorcaserin, obesity
A new weight loss drug has been rejected by the FDA because of numerous concerns about side-effects and limited efficacy. …
Encouraging data for Eisai epilepsy drug
August 24, 2010Sales and Marketing Eisai, epilepsy, perampanel, phase III, seizures, study 306
A new phase III study for Eisai’s perampanel (E2007) suggests the first-in-class treatment is effective as an adjunctive treatment of …
Latest content
Five Facts about cardiovascular disease
